Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322027 | 0.89 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1GRIK1GRIA1 | |
| SCHEMBL5580228 | 0.85 | KMT2A (0.41) | SLC1A3SLC1A2SLC1A1CHEK2 | |
| SCHEMBL21548477 | 0.75 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1GRIK1GRIA1 | |
| SCHEMBL7284399 | 0.75 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1GRIK1GRIA1 | |
| SCHEMBL5322816 | 0.74 | KMT2A (0.41) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5325302 | 0.71 | KIF11 (0.41) | SLC1A3SLC1A2SLC1A1GRIK1GRIA1 | |
| SCHEMBL5319858 | 0.71 | TP53 (0.40) | SLC1A3SLC1A2SLC1A1GRIK1GRIA1 | |
| SCHEMBL6599324 | 0.70 | ESR1 (0.41) | CHEK2 | |
| SCHEMBL7610873 | 0.69 | SLC7A5 (0.56) | — | |
| SCHEMBL7610864 | 0.69 | SLC7A5 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC1A3 4472/4885SLC1A2 4787/4885SLC1A1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.